Newer Intravenous Antibiotics in the Intensive Care Unit: Ceftaroline, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam | Citedby Results | AACN Advanced Critical Care | American Association of Critical-Care Nurses

Skip to Main Content

Skip Nav Destination

Newer Intravenous Antibiotics in the Intensive Care Unit: Ceftaroline, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam

AACN Adv Crit Care (2016) 27 (4): 353–357.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Antimicrobial Multidrug Resistance: Clinical Implications for Infection Management in Critically Ill Patients

Gamze Kalın
Emine Alp
Arthur Chouaikhi
Claire Roger

Microorganisms (2023) 11 (10): 2575.

In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program

Peiyao Jia
Ying Zhu
Hui Zhang
Bin Cheng
Ping Guo
Yingchun Xu
Qiwen Yang

BMC Microbiology (2022) 22 (1)

Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review

Elio Castagnola
Giuliana Cangemi
Alessio Mesini
Carlo Castellani
Antonietta Martelli
Dario Cattaneo
Francesca Mattioli

International Journal of Antimicrobial Agents (2021) 58 (3): 106381.

Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam: a surveillance study from the ATLAS program (2012–2016)

Hui Zhang
Yingchun Xu
Peiyao Jia
Ying Zhu
Ge Zhang
Jingjia Zhang
Simeng Duan
Wei Kang
Tong Wang
Ran Jing
Jingwei Cheng
Yali Liu
Qiwen Yang

Antimicrobial Resistance & Infection Control (2020) 9 (1)

Management of Nosocomial Pneumonia

Earnest Alexander
Gregory M. Susla
Kathryn A. Connor

AACN Advanced Critical Care (2018) 29 (1): 5.